NuVasive Inc

NuVasive — Q4 2017 Earnings Presentation

23 slides from NuVasive's earnings presentation, Feb 26, 2018

  1. Slide 1: Q4/Full-Year 2017 Results Supplemental Presentation

    Q4/Full-Year 2017 Results Supplemental Presentation to Earnings Press Release February 26, 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, leasehold related charges, integration related

  4. Slide 4: Q4 2017 Financial Performance

    Q4 2017 Financial Performance Strong international revenue growth of 34% on a constant currency basis Delivered GAAP operating profit margin of 11.0% and record non-GAAP operating profit margin of 18.2% Drove GAAP EPS of $0.46 and non-GAAP EPS of $0.56, growing at multiples of revenue despite softne

  5. Slide 5: Full-Year 2017 Financial Performance

    Full-Year 2017 Financial Performance Achieved $1 billion revenue milestone Delivered above-market revenue growth at 7.0% Drove international revenue growth of 20%+ throughout year Continued commitment to increased profitability drove operating margin expansion and non-GAAP earnings at 2x revenue gro

  6. Slide 6: Q4 2017 Revenue Drivers

    Q4 2017 Revenue Drivers Revenue (in millions) Q4 2017 Growth Rate Q4 2017 v. Q4 2016 Key Performance Factors U.S. Spinal Hardware Includes all Implants, Fixation & NuVasive Specialized Orthopedics (NSO) $148.4 (3.5%) Case volume growth of ~5% offset by a combination of pricing pressure and product m

  7. Slide 7: Executed on Key Strategic Priorities in 2017

    Executed on Key Strategic Priorities in 2017 Launched LessRay® System Expanded lateral procedural solutions Developed Advanced Materials Science™ portfolio Launched Reline® Small Stature and Reline® Trauma Launched expandable and 3D-printed cages Improved capital structure Authorized $100M share rep

  8. Slide 8: Q4 & Full-Year 2017 P&L Performance

    Q4 & Full-Year 2017 P&L Performance Non-GAAP Measures 4Q17 Actuals 4Q17 YoY Performance Factors FY17 Actuals FY17 YoY Performance Factors Gross Margin 72.4% 290 bps driven by slower than expected ramp up of our manufacturing facility and a slight uptick of pricing pressure 73.9% 270 bps driven by sl

  9. Slide 9: Key Pillars Driving Multi-Faceted Growth

    Key Pillars Driving Multi-Faceted Growth Disruptive Technology Commercial Success Globalization Develop the scale to grow international business to more than double revenue contribution. Compel hospitals and surgeons to use more NuVasive technology and services. Category leader innovating at a gener

  10. Slide 10: Lateral Single-Position Surgery

    Lateral Single-Position Surgery Lateral ALIF XLIF Crestline™ Lateral MAS® Fixation Comprehensive LATERAL PROCEDURAL SOLUTIONS from the upper thoracic to sacrum. XLIF®

  11. Slide 11: Advanced Materials Science Portfolio

    Proprietary Technology: Porous PEEK First-of-its kind porous architecture designed to promote superior bone in-growth, while maintaining the biomechanical and imaging properties of PEEK in general. Proprietary Technology: Modulus® Titanium Integrates endplate porosity with an optimized body lattice

  12. Slide 12: Surgical Intelligence Platform

    Surgical Intelligence Platform* INTEGRATED TO DELIVER PLANNING, SAFETY, IMAGING & NAVIGATION Radiation Reduction C-Arm technology integration High-quality, low-dose imaging Image-stitching capability Navigation Accurate instrument and implant tracking NUVA Procedural Integration Tracking in current

  13. Slide 13: NuVasive Clinical Services

    Serving ~100,000 U.S. cases annually – a national footprint 435+ Neurophysiologists and 35+ Physicians on staff Enhanced Surgical Monitoring & Remote Services A comprehensive spine solution Committed to Achieving Leadership in IONM Quality, Service and Technology #1 Service Leader for Intraoperative

  14. Slide 14: Building Out NUVA International Platform

    Strategy to more than double the International business over next five years at ~35% non-GAAP operating margins. International Revenue (Constant Currency*, In Millions) ~27% CAGR 14 * Constant currency based on 2017 rates. Building Out NUVA International Platform 4% INTERNATIONAL MARKET SHARE - SIGN

  15. Slide 15: Delivering World-Class Self-Manufacturing

    Delivering World-Class Self-Manufacturing $45 Million Investment 100 Pieces of Manufacturing Equipment 180,000 Square Feet Investment in self-manufacturing allows greater control and scalability to support long-term growth and improved margins Further align R&D and Product Development teams to optim

  16. Slide 16: Strong History of Growth and Profitability

    Strong History of Growth and Profitability Global Revenue (In Millions) Non-GAAP Operating Profit Margin $1,030 11.4% 15.4% 16.1% 16.6% ~520 Basis Points ~11% CAGR DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS $762 $811 $962

  17. Slide 17: Driving Improved Adjusted EBITDA Margin

    Driving Improved Adjusted EBITDA Margin DISCIPLINED APPROACH TO DRIVING MEANINGFUL PROFITABILITY IMPROVEMENTS Continued focus on improving the working capital profile and CapEx spending will drive incremental gains in the free cash profile of the company. FUTURE INITIATIVES Significantly reducing in

  18. Slide 18: Impact of U.S. Tax Reform

    Impact of U.S. Tax Reform U.S. TAX RATE REDUCED TO 21% EXPECTED TO BENEFIT EPS & FREE CASH FLOW NuVasive non-GAAP tax rate will drop to ~24% in 2018 and to ~20% and below in future periods. 2018 non-GAAP EPS and Free Cash Flow to benefit in excess of 10%. NuVasive plans to re-invest a portion of add

  19. Slide 19: 2018 Full-Year Guidance

    2018 Full-Year Guidance* $1,095M – $1,105M Full-Year Non-GAAP Operating Profit Margin Full-Year Revenue ~17.6% Full-Year Non-GAAP EPS $2.44 - $2.47 * NuVasive financial performance guidance as of February 26, 2018, inclusive of SafePassage (closed January 2018). ** Organic revenue growth excludes Sa

  20. Slide 20: 2018 Guidance Assumptions

    CONTRIBUTORS TO REVENUE GROWTH International revenue continues to grow 20%+ New product launches in 2H’17 ramp throughout the year In-sourced manufacturing efforts become significantly accretive in 2H’18 Biologics remains pressured for near-term U.S. spine procedural volumes relatively flat NUVASIVE

  21. Slide 21: 2018 Full-Year Financial Performance Guidance

    * NuVasive financial performance guidance as of February 26, 2018, inclusive of SafePassage (closed January 2018). 2018 Full-Year Financial Performance Guidance* Financial Measures FY18 Guidance Performance Drivers Revenue (as reported) $1,095M - $1,105M 6.4% to 7.3% growth Includes SafePassage cont

  22. Slide 22: Steady Progress Against Investment Thesis

    Steady Progress Against Investment Thesis RELENTLESS FOCUS ON DRIVING SHAREHOLDER VALUE International revenue growth 20%+; slower than expected U.S. growth, but still growing multiples of the market and taking share. Remain committed to annual 100 bps of non-GAAP op margin expansion; slower U.S. mar

  23. Slide 23: Slide 23

Nuvasive — Q4 2017 Earnings Presentation on 6ix